The effect of modafinil on fatigue, cognitive functioning and mood in primary brain tumor patients: a multicenter randomized controlled trial chapter 2.3 aBsTracT Background: Fatigue, cognitive deficits, and depression are frequently reported but often undertreated symptoms that can profoundly affect daily life in patients with primary brain tumors (PBTs). To evaluate the effects of the psychostimulant modafinil on fatigue, depression, health-related quality of life (HRQOL) and cognitive functioning in PBT patients, we performed a multicenter, double-blind placebo-controlled crossover trial.
methods: Patients randomly received either six weeks of treatment with modafinil (up to 400mg/day) or six weeks with placebo. After a one week washout period, the opposite treatment was provided. Assessments took place at baseline and immediately after the first and second condition. Patients completed self-reported questionnaires on fatigue (CIS), depression (CES-D), HRQOL (SF-36), and self-perceived cognitive functioning (MOS). They also underwent comprehensive neurocognitive testing.
results: In total, 37 patients participated. Relative to baseline, patients reported lower fatigue severity (CIS) and better motivation (CIS) both in the modafinil (p=0.010 and p=0.021, respectively) and placebo condition (p<0.001 and p=0.027, respectively). The same held for physical health (SF-36 PCS score ; p=0.001 and p=0.008, respectively), working memory (p=0.040 and p=0.043, respectively) and information processing capacity (p=0. 036 and p=0.040, respectively) . No improvement in depressive symptoms was found in either condition.
conclusions: Modafinil did not exceed the effects of placebo with respect to symptom management. Patient accrual was slow, and relatively many patients dropped out during the trial, due mostly to side-effects. Other, preferably nonpharmacological intervention studies should be considered to improve symptom management of PBT patients.
2.3
Modafinil for syMptoM ManageMent in brain tuMor patients inTroducTion Fatigue, cognitive deficits, and depression are frequently reported symptoms in patients with primary brain tumors (PBTs) . 27, 158 Over 80% of PBT patients treated with cranial irradiation experience some degree of somnolence, defined as symptoms of drowsiness, lethargy and fatigue. 10, 11 Unrelated to radiation treatment, 39% of long-term survivors of low-grade glioma (LGG) report severe symptoms of fatigue. 12 In addition to fatigue, cognitive impairments are experienced by 80% of PBT patients. 7 The prevalence of depression in PBT patients ranges from 15% to 27%. 13 All of these symptoms have a large impact on the everyday life of patients and may lead to a significant decrease in health-related quality of life (HRQOL). 34 It is suggested that effective treatment of these symptoms may increase HRQOL, 69 although an optimal strategy to reach this goal has not been defined yet. Modafinil (2-benzhydrylsulfinylethanamide) is a wakefulness-promoting agent that targets fatigue, cognitive functioning, and mood. Although categorized as a psychostimulant, it differs from amphetamine in both physiological and behavioral aspects. It is highly selective for the central nervous system, has a lower abuse potential, and poses a lower risk of adverse effects on organ systems. [159] [160] [161] [162] [163] The precise mechanism of action of modafinil is unknown, but it is theorized to act in a localized manner, utilizing hypocretin, histamine, epinephrine, γ-aminobutyric Presently, we performed a multicenter, double-blind placebo-controlled crossover trial to evaluate the effects of modafinil on fatigue in PBT patients. As fatigue may interact with functional activities and HRQOL, and considering the encouraging study results described above, the effects of modafinil on cognition, mood, and overall HRQOL were also evaluated.
meThods participants
We identified patients who visited the outpatient departments of three tertiary referral centers for neuro-oncology (VU University Medical Center, Amsterdam; Academic Medical Center, Amsterdam; and Medical Center Haaglanden, the Hague) between January 2009 and December 2011. Participants were eligible if they: 1) were ≥ 18 years old, 2) had been diagnosed with a histologically confirmed glioma or meningioma (collectively called primary brain tumor (PBT) throughout this report); and 3) had no signs of tumor recurrence in the last six months. In addition, they were only invited to participate if they reported a heightened experience of fatigue (score >27 on the Checklist Individual Strength (CIS)
188
, as this was our primary outcome measure. Patients were excluded if 1) they had a history of psychiatric disease or symptoms, including depressive disorders; 2) adverse interactions between modafinil and other prescribed medications were expected (e.g., decreased effectiveness of oral contraceptives, levonorgestrelreleasing intrauterine systems and anti-depressants, fluctuations in the effectiveness of antiepileptic drugs acting on similar enzymes); 3) they were unable to communicate in Dutch. A priori sample size calculations based on statistical power (1-β) of 0.80, r=0.30 and α=0.05, yielded 64 patients to be included in the study. The study was approved by the institutional review boards of all participating centers and was registered at http://www.clinicaltrialsregister.eu/ with EudraCT number 2007-003102-10. All patients provided written informed consent.
procedure Eligible patients were introduced to the trial by their treating physician either in person or by mail. The researchers then contacted the patients by telephone to inquire if they were interested in participation. As fatigue was our primary outcome measure, interested patients were asked to fill out the CIS to assess the severity of their complaints and their suitability for participation. After obtaining informed consent, sociodemographic and clinical data were collected from patients' medical records. A pharmacy randomisation system was used to assign participants to either the modafinil or the placebo condition, while patients, treating physicians and researchers were blind to treatment allocation. Patients received six weeks of treatment with either modafinil or placebo starting with a 100 mg dose upon waking and at lunch (200 mg/day in total). After the first week, the dose was doubled to 400 mg/day. After treatment period one, a washout period of one week was applied. Hereafter, the opposite treatment was provided during treatment period two (i.e., those who first received modafinil now received placebo and vice versa). During the trial, patients were asked not to take benzodiazepines as these might interfere with modafinil. Assessments took place at baseline (T1), immediately after treatment period one (after six weeks; T2) and immediately after treatment period two (after twelve weeks; T3). These assessments included self-report questionnaires and neuropsychological assessment, as well as physical and neurological examination carried out by a physician. If patients experienced adverse effects, they were allowed to decrease the medication to the lower dose (200 mg/day) or to stop participating in the trial after consulting the physician involved in the trial.
patient-reported outcomes
Patients were asked to complete self-report questionnaires on measures of fatigue as the primary outcome measure and depression, HRQOL, and subjective cognitive functioning as secondary outcome measures.
Checklist Individual Strength (CIS).
188 Fatigue was assessed with this multidimensional scale, each item scored on a seven-point Likert scale. The CIS includes four aspects of fatigue (fatigue severity, concentration problems, reduced motivation and reduced activity) and a total score. High scores indicate a high level of fatigue, a high level of concentration problems, low motivation and a low activity level. Based on normative controls, a total score between 27 and 35 indicates a heightened experience of fatigue.
Center for Epidemiological Studies Depression Scale (CES-D).
189 This 20-item questionnaire was used to assess symptoms of depression. Participants were asked to indicate, on a four-point scale, how often they feel a statement was applicable to their situation during the last week. Scores range between 0-60, with higher scores indicating more feelings of depression. In the general population, respondents with a total score of ≥16 are considered depressed.
MOS Short-Form Health Survey (SF-36).
19 This HRQOL survey is composed of 36 items that are organized into eight multi-item scales assessing: (1) physical functioning; (2) limitations in role functioning due to physical problems; (3) limitations in role functioning due to emotional problems; (4) pain; (5) vitality; (6) social functioning; (7) mental health; and (8) 
statistical analysis
All statistical analyses were performed with SPSS software version 20. Standard scoring rules were applied to convert the data from the questionnaires. Mean imputation was used to handle missing values within completed questionnaires or neuropsychological assessments. To assess a change in cognitive functioning as accurately as possible, cognitive test scores were converted to Z-scores using the means and standard deviations of the patients' scores at baseline. To achieve data reduction, six cognitive domains were formed (verbal memory; working memory; attentional functioning; information processing; executive functioning; psychomotor speed), see Table 3 . Construction of these cognitive domains was based on a principal component analysis using Varimax rotation with Kaiser normalization performed on the Z-scores of an extensive study among healthy subjects into the biological predictors of cognitive aging.
193 To test whether the outcome measures were normally distributed, Kolmogorov-Smirnov tests were used. Since none of the outcome measures were normally distributed, Wilcoxon signedrank tests were used to determine differences within patients in fatigue, depression, the PCS and MCS scales of the SF-36 (HRQOL), and subjective and objective cognitive functioning. Given the small sample size, no corrections for multiple statistical testing were applied. A p-value of ≤0.05 was considered statistically significant, a p-value of ≤ 0.10 was considered a trend.
resulTs patient characteristics Figure 1 shows details of the participant flow. In total, 155 PBT patients were assessed for eligibility. A total of 39 patients (25.2%) met the inclusion criteria, agreed to participate, and subsequently signed the informed consent form. Thirty-seven patients were assigned randomly to a treatment condition, whereas two patients dropped out before randomization because they were no longer willing to participate. During the trial, overall 12 patients dropped out: seven participants dropped out between T1 and T2, and five patients dropped out between T2 and T3. Reasons for not completing the trial were discontinuation of medication due to side-effects (N=7; patients reported a tingling sensation, nausea, vertigo, anxiety, depression, and feeling fidgety), missed follow-up (N=4), and disease progression (N=1). Table 1 presents sociodemographic and clinical characteristics of the study sample. The mean age of participants was 42.2 years, and more women than men participated (62.2% vs 37.8%). Most participants had a low-grade glioma (37.8%) and the mean time since diagnosis was 49.5 months.
patient-reported outcomes

Fatigue
As can be seen in Table 2 , scores on the CIS scales fatigue severity and reduced motivation were significantly lower after both modafinil (p=0.010 and p=0.021, respectively) and placebo treatment (p<0.001 and p=0.027, respectively) compared with the baseline assessment. both conditions. Although not statistically significant, a trend can be seen for an improvement in reduced activity in the placebo condition (p=0.093) compared with baseline. On the total CISscore, patients' symptoms were alleviated in both the modafinil and placebo condition (p=0.005
and p=0.001, respectively) while scores between the experimental conditions did not differ.
Depression
Scores on the CES-D did not differ significantly between treatment conditions. At baseline, reported scores were only slightly higher (M=15.86, sd=9.49) than in both the modafinil and placebo condition (M=14.16, sd=9.06 and M=13.97, sd=9.44, respectively; p = n.s.). All mean scores were within the non-depressed range (i.e. < 16).
Health-related quality of life
Patients' physical health as measured by the PCS scale improved significantly after both the modafinil (M=46.05, sd=7.96) and placebo condition (M=44.71, sd=9.13) compared with baseline (M=40. 60, sd=7.58; p=0.001 and p=0.008, respectively) . No other significant differences were observed for either physical or mental health scales.
Subjective cognitive complaints
A trend was observed where participants tended to report higher self-perceived cognitive functioning after the placebo condition compared with baseline (p=0.056), see Table 3 .
objective cognitive functioning Table 3 shows that patients improved after both the modafinil and the placebo condition compared with baseline for both the working memory domain (p=0.040 and p=0.043, respectively) and the information processing domain (p=0.036 and p=0.040, respectively). Scores did not differ between the experimental conditions. For attentional functioning, scores improved significantly after the placebo condition compared with baseline (p=0.015) and after modafinil treatment (p=0.013). 
2.3
Modafinil for syMptoM ManageMent in brain tuMor patients discussion Contrary to our hypotheses, we did not find beneficial effects of modafinil on fatigue, depression, overall HRQOL, or cognitive functioning in comparison with placebo. Patients reported a decrease in fatigue severity, an improvement in reduced motivation, and a better overall fatigue score in both the modafinil and the placebo condition compared to baseline, indicating a placebo effect. Counterintuitively, a trend was found for an improvement in the reduced activity scale after the placebo condition, but not after the modafinil condition. For depression, overall HRQOL, and cognitive functioning, we found no difference between the treatment conditions. 
In different study samples of patients with various neurological conditions (Charcot-MarieTooth disease, fibromyalgia, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, narcolepsy), beneficial effects of modafinil for symptoms of fatigue, HRQOL, and cognitive functioning have been shown. 169, 170, 172-174, 176, 181, 183 However, the majority of these studies were not placebo-controlled, and study samples were often relatively small. Although the literature on modafinil for symptom management in PBT patients is scarce, two studies have been reported and both showed positive results. compare their methodology to ours. Importantly, in both studies, no placebo condition was used. As psychological mechanisms such as the presence of expectations prove to be powerful aspects of the experienced effects of medication use, 194 it seems likely that the beneficial effects reported in these previous studies could at least, in part, be attributable to a placebo-effect. Despite this methodological advantage of the present study, there are also significant limitations. In spite of great efforts in recruiting patients, accrual was difficult and ultimately, we did not reach the required sample size. As shown in Figure 1 , almost half of the eligible patients declined participation for several reasons, such as expecting participation to be too burdensome or declining to take more drugs than was strictly necessary. Furthermore, during the trial, a considerable number of patients (32%) dropped out for various reasons, although the majority of these (58.3%) decided to discontinue medication because of side-effects. Interestingly, this also includes patients in the placebo condition who should not have experienced any sideeffects. Although it is not uncommon to experience side-effects with placebo use, 195 the fact that these patients dropped out of the trial does suggest that possibly pharmaceutical trials for symptom management are less suitable for PBT patients. Another study limitation is the heterogeneity of the patient population. We included patients with meningiomas as well as gliomas, while these diseases are not equal in many respects (e.g., nature of the disease, symptoms and treatment, prognosis). Although there is no indication that modafinil would be more effective in one subgroup of PBT patients than in another, it would have been preferable to study the effects of modafinil in a larger, more homogenous group of patients. Despite these limitations, we did find clear differences between the baseline assessment and outcome after both treatment conditions. This suggests that our lack of evidence for beneficial effects of modafinil for symptom management of PBT patients cannot be attributed to the small sample size. Rather, the participants in our sample did not experience better results from modafinil than from placebo. Given the apparent reluctance of a relatively large proportion of PBT patients to participate in pharmacological trials for symptom management, as is shown in the present study as well as in the study by Gehring et al., 43 and given the high percentage of patients suffering from fatigue, cognitive deficits and mood disorders, other intervention studies should be considered. Concerning fatigue, Armstrong and Gilbert 41 provided an interesting overview of the guidelines of the National Comprehensive Cancer Network in relation to PBT patients. Although many nonpharmacologic interventions to treat fatigue (e.g., activity enhancement, physically-based therapy, psychosocial interventions, nutritional consultation, cognitive behavioral therapy for sleep hygiene) have been proven to be effective in the general cancer patient population, randomized controlled trials in PBT patients have not yet been performed. Concerning cognitive deficits, a cognitive function training program has been proven to be effective in PBT patients. 65 For depressive symptoms, nonpharmacological intervention studies in this patient population are also still scarce, although many therapeutic interventions already exist for different cancer patient populations. 196 Because of their unique symptom pattern with neurological and cognitive sequelae, PBT patients are not easily comparable to other cancer patient groups. Therefore, the efficacy of the majority of interventions remains to be evaluated in this particular patient population. We recommend the development of nonpharmacologic interventions aimed specifically at symptom management in PBT patients, which may alleviate their symptom burden substantially and could improve their HRQOL significantly.
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